Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats-Reference-Cited by-同舟云学术

Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats

Published:2024-07-30 Issue:7 Volume:47 Page:1360-1367
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Harada Eri¹²,Sugino Kazumi¹²,Takahara Akira³

Affiliation:

1. EA Pharma Co., Ltd. (Formerly Ajinomoto Pharmaceuticals Co., Ltd.)

2. Ajinomoto Co., Inc.

3. Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/7/47_b24-00265/_pdf

Reference26 articles.

1. 1) Kannel WB, Wilson PW, Moser M, Rich MW. What older adults should know about high cholesterol: a position paper from the Society of Geriatric Cardiology. Am. J. Geriatr. Cardiol., 7, 43–44 (1998).

2. 2) Dzeshka MS, Shahid F, Shantsila A, Lip GYH. Hypertension and atrial fibrillation: an intimate association of epidemiology, pathophysiology, and outcomes. Am. J. Hypertens., 30, 733–755 (2017).

3. 3) Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace, 13, 308–328 (2011).

4. 4) Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace, 13, 473–479 (2011).

5. 5) Harada E, Sugino K, Aimoto M, Takahara A. Effects of the L/N-type Ca²⁺ channel blocker cilnidipine on the cardiac histological remodelling and inducibility of atrial fibrillation in high-salt-fed rats. Biol. Pharm. Bull., 44, 707–713 (2021).